More than one year into the conflict, pharma employees in Ukraine have made heroic efforts to maintain existing clinical studies – but what the country’s doctors and CROs really want is for international companies to start opening new trials again.

More than one year into the conflict, pharma employees in Ukraine have made heroic efforts to maintain existing clinical studies – but what the country’s doctors and CROs really want is for international companies to start opening new trials again.

Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.

The sponsors of Alsitek and quizartinib are hoping that new data generated for the drugs will resolve the concerns raised by the European Medicines Agency when it previously rejected the products for marketing in the EU.